Cumulus Neuroscience Announces Publication in Scientific Reports Demonstrating the NeuLogiq® Platform Is Feasible and Usable for At-Home, Multimodal Cognitive Assessment in People Living with ALS and FTD

Data ReadoutpositiveNeuLogiq®Positive

AI Analysis

Summary

Cumulus Neuroscience announced publication of CNS-102 study results in Scientific Reports demonstrating that the NeuLogiq® Platform is feasible and usable for at-home cognitive assessment in patients with ALS and FTD, with strong usability ratings from participants.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

CNS-102 study published in Scientific Reports showing NeuLogiq® Platform is feasible and usable for at-home multimodal cognitive assessment; 82% of ALS participants rated platform easy to use, 75% positive rating

Importance:5/10

Sentiment:

0.70

neuroscienceALSFTDcognitive assessmentdigital healthpublicationplatform

Read the original article

Published by PR Newswire Biotech on August 18, 2026 4:06 PM

Read Original